The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration
Open accessPublished version of a preprint
Abstract
Antisense oligonucleotides (ASOs) have emerged as a new class of drugs to treat a wide range of diseases, including neurological indications. Spinraza, an ASO that modulates splicing of SMN2 RNA, has shown profound disease modifying effects in Spinal Muscular Atrophy (SMA) patients, energizing efforts to develop ASOs for other neurological diseases. While SMA specifically affects spinal motor neurons, other neurological diseases affect different central nervous system (CNS) regions, neuronal and non-neuronal cells. Therefore, it is important to characterize ASO distribution and activity in all major CNS structures and cell types to have a better understanding of which neurological diseases are amenable to ASO therapy. Here we present for the first time the atlas of ASO distribution and activity in the CNS of mice, rats, and non-human primates (NHP), species commonly used in preclinical therapeutic development. Following central administration of an ASO to rodents, we observe widespread distribution and target RNA reduction throughout the CNS in neurons, oligodendrocytes, astrocytes and microglia. This is also the case in NHP, despite a larger CNS volume and more complex neuroarchitecture. Our results demonstrate that ASO drugs are well suited for treating a wide range of neurological diseases for which no effective treatments are available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“numerous studies suggest that ASOs are not well suited for deep brain structure targets [16,47,52].”
From Elucidating brain transport pathways and cell type-dependent gene silencing of a durable lipid–siRNA conjugate administered into cerebrospinal fluid (2025) · cites this paper as [52]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337
New tools for studying microglia in the mouse and human CNS
Bennett, M. L., Bennett, F. C., Liddelow, S. A., Ajami, B., Zamanian, J. L., Fernhoff, N. B., Mulinyawe, S. B., Bohlen, C. J., Adil, A., Tucker, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525528113 · Cited by 1,804
Bennett, C. F., & Swayze, E. E. (2010) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,431
Self-citationFrom charcot to lou gehrig: deciphering selective motor neuron death in als
Cleveland, D. W., & Rothstein, J. D. (2001) · Nature reviews. Neuroscience · doi:10.1038/35097565 · Cited by 1,389
Finkel, R. S., Chiriboga, C. A., Vajsar, J., Day, J., Montes, J., Vivo, D. C. D., Yamashita, M., Rigo, F., Hung, G., Schneider, E., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31408-8 · Cited by 1,039
Self-citationCrooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Kordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770
Self-citationTargeting Huntingtin Expression in Patients with Huntington’s Disease
Tabrizi, S. J., Leavitt, B. R., Landwehrmeyer, G. B., Wild, E. J., Saft, C., Barker, R. A., Blair, N. F., Craufurd, D., Priller, J., Rickards, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1900907 · Cited by 708
Self-citationAntisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse modelPreprint
Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., & Krainer, A. R. (2010) · Genes & Development · doi:10.1101/gad.1941310 · Cited by 680
Self-citationMiller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., Andres, P. L., Mahoney, K., Allred, P., Alexander, K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70061-9 · Cited by 617
Self-citationCellular uptake and trafficking of antisense oligonucleotides
Crooke, S. T., Wang, S., Vickers, T. A., Shen, W., & Liang, X.-H. (2017) · Nature Biotechnology · doi:10.1038/nbt.3779 · Cited by 582
Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice
Becker, L. A., Huang, B., Bieri, G., Ma, R., Knowles, D. A., Jafar-Nejad, P., Messing, J., Kim, H. J., Soriano, A., Auburger, G., et al. (2017) · Nature · doi:10.1038/nature22038 · Cited by 571
Self-citationPhase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Miller, T., Cudkowicz, M., Shaw, P. J., Andersen, P. M., Atassi, N., Bucelli, R. C., Genge, A., Glass, J., Ladha, S., Ludolph, A. L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2003715 · Cited by 565 · cited 3×
“The Malat1 ASO is the standard 5–10–5 MOE-gapmer design that is frequently used in preclinical research (8,10,12–14,16–18) as well as in ongoing clinical trials (19,20).”
BackgroundMethodJiang, J., Zhu, Q., Gendron, T. F., Saberi, S., McAlonis-Downes, M., Seelman, A., Stauffer, J. E., Jafar-nejad, P., Drenner, K., Schulte, D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.04.006 · Cited by 536
Self-citationDeVos, S. L., Miller, R. L., Schoch, K. M., Holmes, B. B., Kebodeaux, C. S., Wegener, A. J., Chen, G., Shen, T., Tran, H., Nichols, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0481 · Cited by 516
Self-citationAntisense oligonucleotide therapy for neurodegenerative disease
Smith, R. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25424 · Cited by 506
Delivery of Neurotrophic Factors to the Central Nervous System: Pharmacokinetic Considerations
Thorne, R. G., & Frey, W. H. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140120-00003 · Cited by 487
Wahlestedt, C., Golanov, E. V., Yamamoto, S., Yee, F., Ericson, H., Yoo, H., Inturrisi, C. E., & Reis, D. J. (1993) · Nature · doi:10.1038/363260a0 · Cited by 373
Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs
Wu, H., Lima, W. F., Zhang, H., Fan, A., Sun, H., & Crooke, S. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311683200 · Cited by 357
Spinal Muscular Atrophy: A Deficiency in a Ubiquitous Protein; a Motor Neuron-Specific Disease
Monani, U. R. (2005) · Neuron · doi:10.1016/j.neuron.2005.12.001 · Cited by 352
Rigo, F., Chun, S. J., Norris, D. A., Hung, G., Lee, S., Matson, J., Fey, R. A., Gaus, H., Hua, Y., Grundy, J. S., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.212407 · Cited by 283
Self-citationAntisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models
McCampbell, A., Cole, T., Wegener, A. J., Tomassy, G. S., Setnicka, A., Farley, B. J., Schoch, K. M., Hoye, M. L., Shabsovich, M., Sun, L., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99081 · Cited by 279
Self-citationSpinocerebellar ataxias: prospects and challenges for therapy development
Ashizawa, T., Öz, G., & Paulson, H. L. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0051-6 · Cited by 253
Alterman, J. F., Godinho, B. M. D. C., Hassler, M. R., Ferguson, C. M., Echeverria, D., Sapp, E., Haraszti, R. A., Coles, A. H., Conroy, F., Miller, R., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0205-0 · Cited by 227 · cited 1×
“Recently, it was shown that a divalent siRNA has broad distribution and activity in the CNS of NHPs including neurons and GFAP positive astrocytes (50).”
BackgroundMolecular determinants of selective dopaminergic vulnerability in Parkinson’s disease: an update
Brichta, L., & Greengard, P. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00152 · Cited by 227
Yu, R., Kim, T.-W., Hong, A., Watanabe, T., Gaus, H., & Geary, R. (2007) · Drug Metabolism And Disposition · doi:10.1124/dmd.106.012401 · Cited by 226
Zhao, H. T., John, N., Delic, V., Ikeda-Lee, K., Kim, A., Weihofen, A., Swayze, E. E., Kordasiewicz, H. B., West, A. B., & Volpicelli‐Daley, L. A. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.08.002 · Cited by 217
Self-citationReversal of phenotypes in MECP2 duplication mice using genetic rescue or antisense oligonucleotides
Sztainberg, Y., Chen, H., Swann, J. W., Hao, S., Tang, B., Wu, Z., Tang, J., Wan, Y., Liu, Z., Rigo, F., et al. (2015) · Nature · doi:10.1038/nature16159 · Cited by 204
Self-citationAge-dependent SMN expression in disease-relevant tissue and implications for SMA treatment
Ramos, D. M., d’Ydewalle, C. V. O., Gabbeta, V., Dakka, A., Klein, S., Norris, D. A., Matson, J. E., Taylor, S. J., Zaworski, P. G., Prior, T. W., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124120 · Cited by 198
Self-citationTargeted delivery of antisense oligonucleotides to pancreatic β-cells
Ämmälä, C., Drury, W. J., Knerr, L., Ahlstedt, I., Stillemark-Billton, P., Huldt, C. W., Andersson, E.-M., Valeur, E., Jansson‐Löfmark, R., Janzén, D. L. I., et al. (2018) · Science Advances · doi:10.1126/sciadv.aat3386 · Cited by 191
Whitesell, L. J., Geselowitz, D. A., Chavany, C., Fahmy, B., Walbridge, S., Alger, J. R., & Neckers, L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.10.4665 · Cited by 183
Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice
McLoughlin, H. S., Moore, L. R., Chopra, R., Komlo, R., McKenzie, M., Blumenstein, K. G., Zhao, H. T., Kordasiewicz, H. B., Shakkottai, V. G., & Paulson, H. L. (2018) · Annals of Neurology · doi:10.1002/ana.25264 · Cited by 149
Self-citationAntisense oligonucleotides extend survival of prion-infected mice
Raymond, G. J., Zhao, H. T., Race, B., Raymond, L. D., Williams, K., Swayze, E. E., Graffam, S., Le, J., Caron, T. J., Stathopoulos, J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.131175 · Cited by 148
Self-citationTargeting microglia with lentivirus and AAV: Recent advances and remaining challenges
Maes, M. E., Colombo, G., Schulz, R., & Siegert, S. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134310 · Cited by 145
Yu, R. Z., Baker, B. F., Chappell, A. E., Geary, R. S., Cheung, E., & Levin, A. A. (2002) · Analytical Biochemistry · doi:10.1006/abio.2002.5576 · Cited by 138
Prakash, T. P., Yu, J., Migawa, M. T., Kinberger, G. A., Wan, W. B., Østergaard, M. E., Carty, R. L., Vasquez, G., Low, A., Chappell, A. E., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01948 · Cited by 132
Self-citationHung, G., Xiao, X., Peralta, R. Q., Bhattacharjee, G., Murray, S., Norris, D., Guo, S., & Monia, B. P. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0443 · Cited by 126
Self-citationHuntingtin suppression restores cognitive function in a mouse model of Huntington’s disease
Southwell, A. L., Kordasiewicz, H. B., Langbehn, D., Skotte, N. H., Parsons, M. P., Villanueva, E. B., Caron, N. S., Østergaard, M. E., Anderson, L. M., Xie, Y., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar3959 · Cited by 126
Self-citationLi, M., Jancovski, N., Jafar-Nejad, P., Burbano, L. E., Rollo, B., Richards, K., Drew, L., Sedo, A., Heighway, J., Pachernegg, S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152079 · Cited by 115
Self-citationBrain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging
Mazur, C., Powers, B., Zasadny, K., Sullivan, J. M., Dimant, H., Kamme, F., Hesterman, J., Matson, J., Oestergaard, M., Seaman, M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.129240 · Cited by 114
Self-citationSelective tissue targeting of synthetic nucleic acid drugs
Seth, P. P., Tanowitz, M., & Bennett, C. F. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125228 · Cited by 112
Niu, C., Prakash, T. P., Kim, A., Quach, J., Huryn, L. A., Yang, Y., Lopez, E., Jazayeri, A., Hung, G., Sopher, B. L., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aap8677 · Cited by 89
Self-citationAntisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease
Hagemann, T. L., Powers, B. E., Mazur, C., Kim, A., Wheeler, S., Hung, G., Swayze, E. E., & Messing, A. (2017) · Annals of Neurology · doi:10.1002/ana.25118 · Cited by 89
Self-citationSuppression of proteolipid protein rescues Pelizaeus–Merzbacher disease
Elitt, M. S., Barbar, L., Shick, H. E., Powers, B. E., Maeno-Hikichi, Y., Madhavan, M., Allan, K. C., Nawash, B. S., Gevorgyan, A. S., Hung, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2494-3 · Cited by 80
Self-citationContribution of the oligodendrocyte lineage to CNS repair and neurodegenerative pathologies
Tognatta, R., & Miller, R. H. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.04.026 · Cited by 75
Antisense oligodeoxynucleotide inhibits D2 dopamine receptor-mediated behavior and D2 messenger RNA
Weiss, B., Zhou, L.-W., Zhang, S. P., & Qin, Z. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90426-g · Cited by 74
Yaksh, T. L. (1999) · Cited by 67
Messing, A. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64076-5.00044-2 · Cited by 66
MR cisternography and myelography with Gd-DTPA in monkeys.
Chiro, G. D., Knop, R. H., GIRTON, M. E., Dwyer, A. J., Doppman, J. L., Patronas, N. J., Gansow, O. A., Brechbiel, M. W., & Brooks, R. A. (1985) · Radiology · doi:10.1148/radiology.157.2.4048444 · Cited by 60
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.001 · Cited by 56
Sullivan, J. M., Mazur, C., Wolf, D. A., Horky, L. L., Currier, N. V., Fitzsimmons, B., Hesterman, J. Y., Pauplis, R., Haller, S., Powers, B. E., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02461-2 · Cited by 47
Self-citationButler, M., Hayes, C. S., Chappell, A. E., Murray, S., Yaksh, T. L., & Hua, X. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2004.11.038 · Cited by 44
Development of a simple, rapid, and robust intrathecal catheterization method in the rat
Mazur, C., Fitzsimmons, B., Kamme, F., Nichols, B., Powers, B. E., & Wancewicz, E. V. (2017) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2017.02.001 · Cited by 40
Self-citationPharmacokinetics of an intracerebroventricularly administered antibody in rats
Noguchi, Y., Kato, M., Ozeki, K., & Ishigai, M. (2017) · mAbs · doi:10.1080/19420862.2017.1345834 · Cited by 34
Antisense oligonucleotide therapy for SCN2A gain-of-function epilepsyPreprint
Li, M., Jancovski, N., Jafar‐Nejad, P., Burbano, L. E., Rollo, B., Richards, K., Drew, L., Sedó, A., Pachernegg, S., Soriano, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.09.289900 · Cited by 13
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide
Tran, H., Moazami, M. P., Yang, H., McKenna-Yasek, D., Douthwright, C. L., Pinto, C., Metterville, J., Shin, M., Sanil, N., Dooley, C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01557-6 · Cited by 174
Barker, S. J., Thayer, M. B., Kim, C., Tatarakis, D., Simon, M. J., Dial, R., Nilewski, L., Wells, R. C., Zhou, Y., Afetian, M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adi2245 · Cited by 142
Self-citationNucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation
Belgrad, J., Fakih, H. H., & Khvorova, A. (2024) · Nucleic Acid Therapeutics · doi:10.1089/nat.2023.0068 · Cited by 130
Antisense drug discovery and development technology considered in a pharmacological context
Crooke, S. T., Liang, X., Crooke, R. M., Baker, B. F., & Geary, R. S. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114196 · Cited by 109
Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides
Goyenvalle, A., Jimenez-Mallebrera, C., van Roon‐Mom, W., Sewing, S., Krieg, A. Μ., Arechavala‐Gomeza, V., & Andersson, P. U. (2022) · Nucleic Acid Therapeutics · doi:10.1089/nat.2022.0061 · Cited by 102
Metadata
- Authors
- Jafar-nejad, P., Powers, B., Soriano, A., Zhao, H., Norris, D. A., Matson, J., DeBrosse-Serra, B., Watson, J., Narayanan, P., Chun, S. J., Mazur, C., Kordasiewicz, H., Swayze, E. E., & Rigo, F.
- Affiliations
- Ionis Pharmaceuticals Inc. Carlsbad, CA 92010, USA
- Ionis Pharmaceuticals (United States) (US)
- Corresponding author
- Rigo, Frank
- ORCID
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-12-24
- Volume
- 49
- Issue
- 2
- Pages
- 657-673
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC7826274
- OpenAlex
- W3114205754
- Cited by
- 128
- References
- 56
- Citations by year
- 2026: 32 · 2025: 23 · 2024: 24 · 2023: 21 · 2022: 22 · 2021: 5 · 2020: 1
- FWCI
- 3.97
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- antisense oligonucleotides, RNase H, central nervous system distribution, spinal muscular atrophy, SMN2 splicing, oligodendrocytes, astrocytes, microglia, neurons, non-human primates, rodents, centralized management, neurological disease therapy
- MeSH terms
- Animals, Central Nervous System, Female, Injections, Intraventricular, Injections, Spinal, Macaca fascicularis, Male, Neuroglia, Neurons, Organ Specificity, Primates, Tissue Distribution, Oligonucleotides, Antisense, Ribonuclease H, Rats, Sprague-Dawley, In Situ Hybridization, Mice, Rats, RNA, Long Noncoding
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
